Syed Ali

Dr. Syed Ali is a Principal Scientist at Moderna Therapeutics (Cambridge, MA) in the Nonclinical Drug Development Sciences group, where he supports preclinical oncology programs. Previously, he held research roles at Stoke Therapeutics and Pfizer, where he studied mechanisms of antisense oligonucleotide (ASO) therapies for CNS and ocular diseases and engineered stable cell lines to produce monoclonal antibodies for inflammatory disease programs.

Dr. Ali completed his postdoctoral training at Yale University with Prof. Leonard Kaczmarek and earned his Ph.D. from the University of Texas Medical Branch under Prof. Fernanda Laezza, where he investigated ion channel physiology and developed novel therapeutics targeting protein–protein interactions. He has authored multiple peer-reviewed publications spanning mRNA therapeutics, antisense oligonucleotides, and small-molecule drug discovery.